First Horizon Advisors’s Sarepta Therapeutics SRPT Stock Holding History

First Horizon Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$3.78K	Sell	221 -47	-18%	-$2K	﹤0.01%	1897
2025 Q1	$17.1K	Sell	268 -14	-5%	-$1.47K	﹤0.01%	1390
2024 Q4	$34.3K	Hold	282	–	–	﹤0.01%	1118
2024 Q3	$35.2K	Sell	282 -7	-2%	-$968	﹤0.01%	1144
2024 Q2	$45.7K	Buy	289 +21	+8%	+$2.7K	﹤0.01%	960
2024 Q1	$34.7K	Hold	268	–	–	﹤0.01%	1122
2023 Q4	$25.8K	Buy	268 +20	+8%	+$1.92K	﹤0.01%	1239
2023 Q3	$30.1K	Buy	248 +3	+1%	+$339	﹤0.01%	1084
2023 Q2	$28.1K	Buy	245 +185	+308%	+$23.9K	﹤0.01%	1140
2023 Q1	$8.27K	Buy	60 +26	+76%	+$3.37K	﹤0.01%	1624
2022 Q4	$4.41K	Hold	34	–	–	﹤0.01%	1827
2022 Q3	$3K	Hold	34	–	–	﹤0.01%	1929
2022 Q2	$2K	Buy	+34	New	+$2.5K	﹤0.01%	2124
2022 Q1	–	Sell	-34	Closed	-$3K	–	2246
2021 Q4	$3K	Sell	34 -7	-17%	-$598	﹤0.01%	1911
2021 Q3	$3K	Buy	41 +3	+8%	+$231	﹤0.01%	1901
2021 Q2	$2K	Hold	38	–	–	﹤0.01%	1797
2021 Q1	$2K	Buy	38 +3	+9%	+$277	﹤0.01%	1699
2020 Q4	$6K	Buy	35 +14	+67%	+$2.07K	﹤0.01%	1187
2020 Q3	$2K	Buy	21 +2	+11%	+$304	﹤0.01%	1320
2020 Q2	$3K	Hold	19	–	–	﹤0.01%	1264
2020 Q1	$1K	Buy	+19	New	+$2.17K	﹤0.01%	1314

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

First Horizon Advisors's SRPT Position: Q2 2025 in Review

First Horizon Advisors reduced its Sarepta Therapeutics (SRPT) stake by 18% in Q2 2025, selling an estimated $2K and leaving 221 shares worth $3.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

First Horizon Advisors first reported a position in SRPT in Q1 2020 and has held it in 21 quarters since. The position peaked at $45.7K in Q2 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

First Horizon Advisors held 221 shares of Sarepta Therapeutics worth $3.78K as of Q2 2025.
First Horizon Advisors sold 47 Sarepta Therapeutics shares in Q2 2025, an estimated $2K.
Sarepta Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1897 holding.
First Horizon Advisors first reported a position in Sarepta Therapeutics in Q1 2020 and has held it in 21 quarters since.
First Horizon Advisors's Sarepta Therapeutics position peaked at $45.7K in Q2 2024.
363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.